Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT05566457
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT05546255
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Low-dose Radiotherapy in iNHL
- Conditions
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 73
- Registration Number
- NCT05543070
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT05522894
Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection
- Conditions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 159
- Registration Number
- NCT05499195
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT05499715
- Locations
- 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China
The Clinical Effect of Adaptive Posture-balance Cardiac Rehabilitation Exercise on Cardiovascular Diseases
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT05496153
- Locations
- 🇨🇳
Tianjin Chest Hospital, Tianjin, Tianjin, China
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 588
- Registration Number
- NCT05484024
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, China
🇨🇳National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection
- Conditions
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 3591
- Registration Number
- NCT05460403
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, Chaoyang, China
Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 1821
- Registration Number
- NCT05441098
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China